stockportfolio.pro
Stocks / PGEN vs RXRX
PGEN vs RXRX
Precigen, Inc. and Recursion Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Precigen, Inc. (PGEN) | Recursion Pharmaceuticals, Inc. (RXRX) | |
|---|---|---|
| Market cap | $1.6B | $1.6B |
| Revenue (latest FY) | $9.68M | $74.26M |
| Net income (latest FY) | $-250.64M | $-644.76M |
| Revenue growth (5y CAGR) | -21.3% | 79.7% |
| Net margin | -2588.2% | -868.3% |
| Return on equity | -1198.6% | -57.0% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open PGEN — free Open RXRX — freeFrequently asked questions
Which is bigger, PGEN or RXRX?
Recursion Pharmaceuticals, Inc. is larger by market capitalization — $1.6B versus $1.6B.
Which grows faster, PGEN or RXRX?
Over the last five fiscal years, Recursion Pharmaceuticals, Inc. grew revenue faster — 79.7%/yr versus -21.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.